A trial for preparation of mucosal vaccine for Foot and Mouth Disease Virus / Manar Essam Mohamed Khalifa ; Supervised Hussein Aly Hussein Ahmed , Ayman Hany Eldeeb , Sayed Zeidan
Material type: TextLanguage: English Publication details: Cairo : Manar Essam Mohamed Khalifa , 2017Description: 128 P. : charts , facsimiles ; 25cmOther title:- محاولة لتحضير لقاح مخاطي لفيروس مرض الحمى القلاعية [Added title page title]
- Issued also as CD
Item type | Current library | Home library | Call number | Copy number | Status | Date due | Barcode | |
---|---|---|---|---|---|---|---|---|
Thesis | قاعة الرسائل الجامعية - الدور الاول | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.10.17.M.Sc.2017.Ma.T (Browse shelf(Opens below)) | Not for loan | 01010110072530000 | |||
CD - Rom | مخـــزن الرســائل الجـــامعية - البدروم | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.10.17.M.Sc.2017.Ma.T (Browse shelf(Opens below)) | 72530.CD | Not for loan | 01020110072530000 |
Thesis (M.Sc.) - Cairo University - Faculty of Veterinary Medicine - Department of Virology
Mucosal vaccines for foot and mouth disease virus are expected to block viral entry, thus, limiting (FMDV) spread in the cattle herd. Immunization strategy based on both mucosal and systemic immunity platforms is greatly needed to control FMD. In this study, several immunization strategies, using two foot and mouth disease vaccine formulations, including Montanide ISA 206 oil - based FMD inactivated vaccine and Montanide IMS 1313 VG N PR - based concentrated semi-purified FMD mucosal vaccine were applied. Results of intra nasal immunization with the prepared FMD mucosal vaccine given, once or twice, induced IgA levels in both nasal and salivary secretions besides a high response of lymphocyte proliferation with protection levels reaching 20% and 40%, respectively, in a challenge trial in cattle. Prime boost strategy based on the administration of mucosal vaccine followed by inactivated vaccine appeared to be the most potent strategy, achieving 100% protection against an FMDV challenge. Indeed, the study reports the efficacy of the prepared IMS 1313 FMD mucosal vaccine and the possible use of this vaccine in the context of different vaccination strategies to control FMDV
Issued also as CD
There are no comments on this title.